Bristol-myers Squibb

This early-phase study tested a new drug called BMS-986315, both by itself and combined with other cancer treatments, in people with advanced solid tumors. The main goals were to check the safety of the drug and see if it showed any signs of helping to shrink tumors. The study in…

This study tested whether combining the immunotherapy drug nivolumab with the targeted therapy trametinib, with or without another immunotherapy called ipilimumab, could help control advanced colorectal cancer that had spread and stopped responding to prior treatments. It involve…

This study tested a 30-week course of the drug mavacamten in 38 Japanese adults with a specific heart condition called symptomatic obstructive hypertrophic cardiomyopathy (HCM). The goal was to see if the drug could safely improve symptoms, physical limitations, and how well the …

This study tested whether adding an immunotherapy drug (nivolumab) to one of three other cancer drugs could help men with advanced prostate cancer that had spread and stopped responding to standard hormone therapy. It involved 292 participants and aimed to see if these combinatio…

This early-stage study tested a new way to give the cancer immunotherapy drug nivolumab—as an injection under the skin instead of into a vein. It involved 139 people with various advanced cancers, including lung, kidney, and skin cancers. The main goal was to see how the body pro…

This large study tested whether a drug called nivolumab could help keep cancer from coming back in people who had surgery for esophageal cancer. Nearly 800 patients who had already completed chemotherapy and radiation before surgery received either nivolumab or a placebo (dummy d…

This large study tested whether immunotherapy drugs (nivolumab alone or combined with ipilimumab) work better than standard chemotherapy for people with advanced lung cancer that hasn't been treated before. Researchers enrolled 2,747 participants to compare how long patients live…

This study tested a new drug called BMS-813160, given alone or combined with standard chemotherapy and/or an immunotherapy drug (nivolumab), in people with advanced colorectal or pancreatic cancer that had spread. The main goals were to check the safety of these combinations, see…

This early-stage study tested a new drug, BMS-986288, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and see if the treatments …

This study looked back at medical records to understand how well the medication mavacamten works for people with a specific heart condition called obstructive hypertrophic cardiomyopathy (oHCM) in real-world Canadian clinics. Researchers surveyed doctors and reviewed the charts o…

This study tested new immunotherapy drugs (nivolumab alone and combined with ipilimumab) for people with advanced liver cancer that could not be treated with surgery. It aimed to find safe doses and see if these drugs could shrink tumors and help patients live longer. The trial i…

This large study tested whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy could help people with advanced esophageal cancer live longer or delay cancer growth. It involved 970 adults whose cancer couldn't be removed by surgery and …

This early-stage study aimed to find a safe dose for a new cancer drug called BMS-986408. It tested the drug alone and combined with other approved cancer immunotherapies in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was…

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) for people with advanced liver cancer that had worsened after standard pill-based treatments. The main goal was to see if the drug combo could shrink tumors and control the cancer. Researche…

This early-stage study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) in children and young adults whose Hodgkin or non-Hodgkin lymphoma had come back or did not respond to standard treatments. The main goals were to find a safe dose and see if the…

This study tested whether using two immunotherapy drugs together (nivolumab and ipilimumab) could help men with advanced prostate cancer that had spread and was no longer responding to standard hormone therapy. It compared this combination against using one of the drugs alone or …

This study monitored the long-term safety of mavacamten, a medication for hypertrophic cardiomyopathy (a condition where the heart muscle thickens). It included 314 adults who had already completed earlier trials testing this drug. Researchers tracked side effects and safety over…

This Phase 3 trial tested whether the drug mavacamten could improve symptoms and exercise capacity in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a genetic heart condition that causes the heart muscle to thicken. The study involved 580 participants…

This study looked at how well the medication mavacamten worked for 163 real patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. Researchers at a single US hospital collected information on patients' symp…

This study tested a new targeted drug called farletuzumab ecteribulin (MORAb-202) against standard chemotherapy for women with a specific, hard-to-treat form of ovarian cancer that had stopped responding to platinum-based drugs. The goal was to see if the new drug was safer and m…

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and more effective for people with untreated advanced liver cancer. It involved 83 participants who were randomly assigned to receive either the three-d…

This study observed 450 people with relapsing multiple sclerosis in Germany who were already prescribed ozanimod (Zeposia) by their doctor. Over three years, it tracked how long patients stayed on the medication, how well it controlled their MS symptoms, and how it affected their…

This study tested the safety and initial effectiveness of a combination of two immunotherapy drugs, nivolumab and ipilimumab, in Chinese patients with advanced solid tumors that had returned or spread after prior treatment. The main goals were to see what side effects occurred an…

This study observed 104 people with relapsing-remitting multiple sclerosis (RRMS) in Italy who switched from their first or second disease-modifying therapy to a newer oral medication called ozanimod. Researchers tracked why patients switched (like side effects or the treatment n…

This study compared two different first treatments for Chinese patients with advanced mesothelioma, a cancer of the lung lining that cannot be removed by surgery. Researchers tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better and is sa…

This study collected real-world information from 112 patients in France with acute myeloid leukemia (AML) who were in remission. It aimed to understand how well an oral maintenance drug called azacitidine works to prevent the cancer from coming back and to describe the patients' …

This study tested a new drug called BMS-986322 to see if it could safely reduce the skin plaques and symptoms of moderate-to-severe psoriasis. It involved 109 adults with significant psoriasis coverage and compared the drug's effects to a placebo over 12 weeks. The main goal was …

This study looked back at medical records to see how well a combination of immunotherapy (nivolumab) and chemotherapy worked for Argentinian patients with early-stage, operable lung cancer. The goal was to see if this treatment given before surgery could completely eliminate the …

This study tested the safety and early effectiveness of combining two immunotherapy drugs, nivolumab and daratumumab, for people with multiple myeloma that has returned or stopped responding to standard treatments. It involved about 320 participants with various blood cancers, fo…

This study observed how well patients with advanced non-small cell lung cancer lived after receiving the drug nivolumab in real-world clinics in Greece and Cyprus. It followed 212 patients who had already tried chemotherapy, tracking their survival at 1, 2, and 3 years, their qua…

This study tested whether an oral medication called deucravacitinib could clear or nearly clear scalp psoriasis better than a placebo. It involved 154 adults with moderate-to-severe scalp psoriasis who had not gotten enough relief from topical creams. Researchers measured how wel…

This study tested the safety and effectiveness of a new immunotherapy drug called BMS-986016 (relatlimab), given alone and in combination with the established drug nivolumab. It involved over 1,400 people with advanced solid tumors that had spread or could not be removed by surge…

This study tested if adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced non-small cell lung cancer that has spread. It involved 719 adults with newly diagnosed stage IV lung c…

This early-stage study tested a new drug called BMS-986249, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check if the treatments were safe, f…

This study tested the safety and effectiveness of an experimental drug called BMS-986253 when given alongside established immunotherapy drugs (nivolumab with or without ipilimumab). It involved 281 people with advanced, hard-to-treat cancers, including melanoma. The main goals we…

This study tested whether an experimental drug called BMS-986278 could help people with pulmonary fibrosis, a condition that causes scarring in the lungs. 403 participants were randomly assigned to receive either the drug or a placebo for 26 weeks to see if it could slow the decl…

This completed Phase 2 trial tested whether the immunotherapy drug nivolumab, either alone or combined with other cancer drugs, could meaningfully shrink tumors in people with advanced colon cancer that had returned or spread. The study enrolled 385 participants whose tumors had …

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) in Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the safety of the drugs in the body and see early signs of whe…

This early-stage study tested the safety and effects of an experimental drug called BMS-986326 in adults with moderate-to-severe eczema. Researchers gave 64 participants either the drug or a placebo to check for side effects and measure how the drug behaves in the body. The main …

This study tested whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy before lung cancer surgery is better than chemotherapy alone. It involved 505 people with early-stage, operable non-small cell lung cancer. The goal was to see if …

This study tested whether a medication called deucravacitinib could improve the daily life and well-being of people living with plaque psoriasis. It involved 180 adults with moderate-to-severe psoriasis who were already candidates for systemic treatment. Participants were randoml…

This study aimed to understand how much of a medication called deucravacitinib, used for conditions like psoriasis and arthritis, passes into breast milk. Eight healthy, lactating women received a single dose, and researchers carefully measured the drug levels in their milk and b…

This study tested how an investigational cancer drug called repotrectinib affects the body's processing of several common medications. Researchers gave repotrectinib alongside drugs like metformin (for diabetes), digoxin (for heart conditions), and others to 30 healthy adult volu…

This study aimed to understand how the immunotherapy drug nivolumab works for people with advanced lung cancer in everyday medical practice. Researchers observed 535 patients in France who had already tried chemotherapy and whose doctors had decided to start nivolumab. The goal w…

This was an early-stage study to check the safety of a new drug called BMS-986419 in healthy people. Researchers gave the drug to 74 volunteers to see how their bodies handled it and to carefully measure if it had any effect on their heart rhythm. The main goal was to gather basi…

This study looked at whether certain arthritis medications might increase the risk of developing cancer. Researchers analyzed health records from over 140,000 Swedish adults with rheumatoid or psoriatic arthritis who were taking various arthritis drugs. The goal was to understand…

This study looked back at medical records to understand how doctors in Japan treat patients with lower-risk myelodysplastic syndromes (MDS), a type of blood disorder. Researchers analyzed data from 177 patients diagnosed between 2017 and 2022 to see what treatments were used, how…

This study looked back at the medical records of 418 adults in the US with a lower-risk type of myelodysplastic syndrome (MDS), a bone marrow disorder. The goal was to understand how patients fared in real life when treated with the drug luspatercept for anemia, compared to anoth…

This early-stage study tested a single dose of an experimental antibody drug, BMS-986446, in 46 healthy people. The main goal was to understand how the body processes the drug when given as a shot under the skin versus into a vein, and to check for any side effects. This type of …

This was an early-stage study to check the safety of a new drug called BMS-986460 and see how it moves through the body. It involved 85 healthy adult male volunteers. The research tested different pill versions and measured side effects and drug levels in the blood.

This study measured how a single dose of the cancer drug repotrectinib behaves in people with moderate or severe liver impairment compared to healthy people. Researchers enrolled 18 adults to understand if liver problems change how the drug moves through the body. The goal was to…

This study looked back at the real-world experiences of 100 adults with stage III melanoma who received one of two combination drug treatments before surgery. Researchers collected information about the patients, their treatment details, side effects, and long-term outcomes like …

This study aimed to monitor the long-term safety of the arthritis drug abatacept after it was approved for use. It tracked over 38,000 people in Denmark with rheumatoid or psoriatic arthritis who were taking the drug. The main goal was to see how often certain cancers, especially…

This study looked back at medical records to understand how well the drug nivolumab worked in real-world practice for 260 patients in China with advanced stomach cancer. It did not test a new treatment but collected information on how long the cancer was controlled and how patien…

This study tested how eating food affects the levels of a new drug called Admilparant in the body. It involved 56 healthy volunteers who took the drug either with or without food. The main goal was to measure how much of the drug gets into the bloodstream under these different co…

This study looked back at the medical records of 327 adults with advanced kidney cancer to see how they fared in everyday medical practice. It compared two different combination drug treatments: Nivolumab with Ipilimumab, and Pembrolizumab with Lenvatinib. The goal was to underst…

This early-stage study tested the safety and heart effects of an experimental drug called BMS-986278 in healthy people. The two-part trial involved 42 healthy volunteers to check for side effects and see how the drug moves through the body. Researchers specifically measured if th…

This French study asked cancer patients how satisfied they were with their care when switching from receiving immunotherapy at a hospital to receiving it at home. Researchers surveyed 49 adults with solid tumors who were already approved for home treatment. The goal was to unders…

This early-stage study tested how a single dose of an experimental drug, BMS-986278, is processed by the body in people with different levels of kidney function. It involved 27 participants, including healthy volunteers and people with severe kidney disease or kidney failure requ…